Katherine Sullivan-Reed

Katherine Sullivan-Reed

Auto-generated profile, based on publicly available information

Katherine Sullivan-Reed

Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
DNA polymerase theta (Polθ, encoded by POLQ gene) plays an essential role in Polθ-mediated end-joining (TMEJ) of DNA double-strand breaks (DSB). Inhibition of Polθ is synthetic lethal in homologous recombination (HR)-deficient tumor cells. However, DSBs can be also repaired by PARP1 and RAD52-mediated mechanisms. Because leukemia cells accumulate spontaneous DSBs, we tested if simultaneous targeting of Polθ and PARP1 or RAD52 enhance the synthetic lethal effect in HR-deficient leukemia cells. Transformation potential of the oncogenes inducing BRCA1/2-deficiency (BCR-ABL1 and AML1-ETO) was severely limited in Polq−/−;Parp1−/− and Polq−/−;Rad52−/− cells when compared with single knockouts, which was associated with accumulation of DSBs. Small-molecule inhibitor of Polθ (Polθi) when combined with PARP or RAD52 inhibitors (PARPi, RAD52i) caused accumulation of DSBs and exerted increased effect against HR-deficient leukemia and myeloproliferative neoplasm cells. Implications: In conclusion, we show that PARPi or RAD52i might improve therapeutic effect of Polθi against HR-deficient leukemias.

27 November 2025
Verified
Other
Open access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
S3. Simultaneous inhibition of Polθ helicase and DNA polymerase activity exerted synergistic effect against RAD54-/- leukemia cells.

27 November 2025
Verified
Other
Open access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
S1. Genetic aberrations and mRNA expression variabilities of POLQ, PARP1 and RAD52 do not coexist in 519 AML samples from the BEAT-AML cohort.

27 November 2025
Verified
Other
Open access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
S5. Targeting Polθ + PARP1 and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells.

12 July 2023
Verified
Other
Open access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
S2. Phenotype of Polq-/-;Parp1-/- and Polq-/-;Rad52-/- mice.

12 July 2023
Verified
Other
Open access
PDF file
KSKatherine Sullivan-Reed
Katherine Sullivan-Reed
MTMonika Toma
Monika Toma
MDMałgorzata Drzewiecka
Małgorzata Drzewiecka
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
RNReza Nejati
Reza Nejati
TSTomasz Skorski
Tomasz Skorski
S4. Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR -deficient MPN cells.